We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+11.92%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$191M
AUM Growth
-$59.3M
(-24%)
Cap. Flow
-$76.2M
Cap. Flow
% of AUM
-39.78%
Top 10 Holdings %
Top 10 Hldgs %
5.8%
Holding
489
New
53
Increased
164
Reduced
226
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
D.R. Horton
DHI
|
+$888K |
| 2 |
Lennar Class A
LEN
|
+$880K |
| 3 |
Microchip Technology
MCHP
|
+$860K |
| 4 |
Ametek
AME
|
+$859K |
| 5 |
Home Depot
HD
|
+$853K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Steel Dynamics
STLD
|
+$1.62M |
| 2 |
Cheniere Energy
CQP
|
+$1.53M |
| 3 |
STOR
STORE Capital Corporation
STOR
|
+$1.44M |
| 4 |
NOA
North American Construction
NOA
|
+$1.43M |
| 5 |
STR
Sitio Royalties
STR
|
+$1.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 26.88% |
| 2 | Financials | 12.6% |
| 3 | Technology | 10.15% |
| 4 | Materials | 9.55% |
| 5 | Real Estate | 8.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Replimune Group
REPL
$448M
| $137K | 0.07% |
5,019
-2,134
| -30% | -$44.3K |
|
|
MORF
377
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $136K | 0.07% |
5,099
+31
| +0.6% | +$847 |
|
|
VTYX
378
DELISTED
Ventyx Biosciences
VTYX
| $135K | 0.07% |
4,125
-3,898
| -49% | -$115K |
|
379
uniQure
QURE
$2.77B
| $135K | 0.07% |
5,955
-1,847
| -24% | -$39.8K |
|
|
ISEE
380
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $135K | 0.07% |
6,287
-4,788
| -43% | -$102K |
|
|
KRTX
381
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $135K | 0.07% |
685
-365
| -35% | -$78.3K |
|
382
Keros Therapeutics
KROS
$198M
| $134K | 0.07% |
2,788
-1,037
| -27% | -$48.4K |
|
383
Cogent Biosciences
COGT
$6.76B
| $134K | 0.07% |
+11,576
| New | +$143K |
|
384
Regenxbio
RGNX
$617M
| $134K | 0.07% |
5,893
+645
| +12% | +$14.6K |
|
385
Iovance Biotherapeutics
IOVA
$2.07B
| $133K | 0.07% |
20,782
+7,263
| +54% | +$56.7K |
|
386
Kura Oncology
KURA
$802M
| $132K | 0.07% |
10,635
+2,985
| +39% | +$43.4K |
|
|
ACLX
387
DELISTED
Arcellx
ACLX
| $132K | 0.07% |
+4,245
| New | +$97.4K |
|
|
NGM
388
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $131K | 0.07% |
26,181
+17,854
| +214% | +$112K |
|
|
ITOS
389
DELISTED
iTeos Therapeutics
ITOS
| $129K | 0.07% |
6,620
+792
| +14% | +$15.5K |
|
|
BCYC
390
Bicycle Therapeutics
BCYC
$269M
| $129K | 0.07% |
4,361
-3,648
| -46% | -$97.9K |
|
|
DVAX
391
DELISTED
Dynavax Technologies
DVAX
| $129K | 0.07% |
12,127
+2,157
| +22% | +$25.1K |
|
|
NUVL
392
DELISTED
Nuvalent
NUVL
| $129K | 0.07% |
+4,330
| New | +$121K |
|
|
DICE
393
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $129K | 0.07% |
4,127
-3,413
| -45% | -$111K |
|
|
TVRD
394
Tvardi Therapeutics
TVRD
$22.2M
| $129K | 0.07% |
333
-39
| -10% | -$14.8K |
|
395
Xencor
XNCR
$1.45B
| $128K | 0.07% |
4,911
-309
| -6% | -$8.64K |
|
|
SGMO
396
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $127K | 0.07% |
40,600
+8,949
| +28% | +$34.7K |
|
397
Arvinas
ARVN
$530M
| $127K | 0.07% |
3,721
+821
| +28% | +$34.5K |
|
398
4D Molecular Therapeutics
FDMT
$498M
| $127K | 0.07% |
+5,731
| New | +$88.5K |
|
399
Seres Therapeutics
MCRB
$45.8M
| $127K | 0.07% |
1,131
-804
| -42% | -$108K |
|
400
Denali Therapeutics
DNLI
$3.78B
| $127K | 0.07% |
4,552
-323
| -7% | -$9.61K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q4 2022 Portfolio in Review
As of Q4 2022, Virtus ETF Advisers held 489 positions worth $191M, down 24% from $251M the previous quarter. Its ten largest holdings account for 5.8% of the portfolio.
Virtus ETF Advisers withdrew a net $76.2M in Q4 2022, closing 46 positions and reducing 226 holdings. Its most notable exit was iShares JPMorgan USD Emerging Markets Bond ETF, an estimated $877K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 19% a quarter earlier, followed by Financials and Technology.
Against the trend, Virtus ETF Advisers opened a new position in D.R. Horton worth $987K.
- Virtus ETF Advisers's largest Q4 2022 buy was D.R. Horton: 11,078 shares worth $987K.
- Virtus ETF Advisers added most to Qualcomm in Q4 2022, an estimated $271K increase.
- Virtus ETF Advisers's biggest Q4 2022 reduction was Steel Dynamics, cutting an estimated $1.62M.
- Virtus ETF Advisers fully exited iShares JPMorgan USD Emerging Markets Bond ETF in Q4 2022, selling an estimated $877K.
- Virtus ETF Advisers's ten largest holdings make up 5.8% of its $191M portfolio in Q4 2022.
- Virtus ETF Advisers opened 53 new positions and closed 46 in Q4 2022.
- Virtus ETF Advisers's portfolio value fell 24% quarter-over-quarter to $191M.
Based on Virtus ETF Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.